201. M15.4 Low maternal PlGF across pregnancy identifies a subset of women with preterm preeclampsia; type 1 vs. type 2 preeclampsia?
- Author
-
David C. Sogin, Robert W. Powers, Saul A. Datwyler, James M. Roberts, Dominick Pucci, Robin E. Gandley, Don Laird, Arun Jeyabalan, and Daniel A. Plymire
- Subjects
Placental growth factor ,Pregnancy ,medicine.medical_specialty ,business.industry ,Obstetrics ,Obstetrics and Gynecology ,Gestational age ,Context (language use) ,medicine.disease ,female genital diseases and pregnancy complications ,Pathophysiology ,Preeclampsia ,Internal Medicine ,medicine ,Gestation ,Small for gestational age ,business ,reproductive and urinary physiology - Abstract
Context: Preeclampsia is a heterogeneous syndrome that affects 3-5% of all pregnancies. An imbalance of the anti and pro-angiogenic factors, soluble receptor fms-like tyrosine kinase 1 (sFlt1) and placental growth factor (PlGF), are thought to contribute to the pathophysiology of preeclampsia. Objective: The aim of the study was to investigate the pattern of maternal sFlt1 and PlGF across pregnancy, and relate these factors to pregnancy outcome in preeclampsia and uncomplicated pregnancies. Study Design: Maternal plasma PlGF and sFlt1 were quantified by specific immunoassays in longitudinal samples from 50 women who developed preeclampsia and 250 normotensive controls. Results: PlGF was lower by 15 to 25 weeks gestation (p
- Published
- 2010
- Full Text
- View/download PDF